Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors
Key facts
- Who runs it
- Sanofi
- Where
- Houston, United StatesSee the siteAlso in 5 other countries, 10 sites
- Trial code
- NCT05013554
- EU 2023-506852-26-00
- EudraCT 2021-000086-32
- U1111-1253-2233
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 44 people enrolled
- Started
- 16 Aug 2021
- Ended
- 15 Jan 2024
- Type of study
- Interventional, 5 groups
- Treatments tested
- SAR443216 IV
- SAR443216 SC
- Record updated
- 15 September 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Participants must be ≥ 18 years of age
- Histologically or cytologically confirmed diagnosis of metastatic solid tumors
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- All participants should have at least 1 measurable disease per RECIST v1.1. An irradiated lesion can be considered measurable only if progression has been demonstrated on the irradiated lesion
- Body weight within [45 - 150 kg] (inclusive)
- All Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
- Capable of giving signed informed consent
Who cannot take part
- Prior solid organ or hematologic transplant
- Participation in a concurrent clinical study in the treatment period
- Any clinically significant cardiac disease
- History of or current interstitial lung disease or pneumonitis
- Uncontrolled or unresolved acute renal failure
- Known positivity with human immunodeficiency virus (HIV), known active hepatitis A, B, and C, or uncontrolled chronic or ongoing infectious requiring parenteral treatment
- Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions; The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial
- Receipt of a live-virus vaccination within 28 days of planned treatment start
- Inadequate hematologic, hepatic and renal function
Where in United States
Also in 5 other countries, 10 sites
- ~University of Texas - MD Anderson Cancer Center Site Number : 8400002Houston, United States
About the trial
What the trial wants to find out
Primary Objectives:
Read full original descriptionShow less
Part 1 (Dose Escalation)
* To determine the MTD/maximum administered dose (MAD) of SAR443216 administered as a single agent in participants with HER2 expressing solid tumors and determine the RD(s) for intravenous (IV) and subcutaneous (SC) administration in the dose escalation part. * To determine the safety of SAR443216 after intravenous (IV) and subcutaneous (SC) administration.
Part 2 (Dose expansion)
• To assess preliminary clinical activity of single agent SAR443216 at the RD(s) in participants with HER2 expressing solid tumors, with various levels of HER2 expression.
Secondary Objectives:
Part 1 • To assess preliminary clinical activity of single agent SAR443216 after IV and SC administration at the RD(s) in participants with HER2 expressing solid tumors, with various levels of HER2 expression.
Part 2
• To determine the safety of SAR443216.
Part 1 and 2
* To characterize the pharmacokinetic (PK) profile of SAR443216 when administered as a single agent after IV and SC (Part 1 only) administration. * To evaluate the immunogenicity of SAR443216 after IV and SC administration. * To assess preliminary clinical activity of single agent SAR443216 at the RD(s) in participants with HER2 expressing solid tumors, with various levels of HER2 expression.
The 5 groups in the trial
- SAR443216-Dose EscalationTreatment being tested
Participants with metastatic solid tumors that express HER2 in tumor tissue and/or with HER2 aberration will receive SAR443216 as intravenous (IV) infusion or subcutaneous (SC) injection.
Treatment: SAR443216 IV and SAR443216 SC
- SAR443216-Dose Expansion - metastatic breast cancers with HER2 high expression: Cohort ATreatment being tested
Participants with metastatic breast cancers with HER2 high expression (with amplification) will receive SAR443216 as intravenous (IV) infusion.
Treatment: SAR443216 IV
- SAR443216-Dose Expansion- metastatic breast cancers with HER2 low expression: Cohort BTreatment being tested
Participants with metastatic breast cancers with HER2 low expression or HER2 mutation (without amplification) will receive SAR443216 as intravenous (IV) infusion.
Treatment: SAR443216 IV
- SAR443216-Dose Expansion- metastatic gastric cancers with HER2 low expression: Cohort CTreatment being tested
Participants with metastatic gastric cancers with HER2 low expression or HER2 mutation (without amplification) will receive SAR443216 as intravenous (IV) infusion.
Treatment: SAR443216 IV
- SAR443216-Dose Expansion - metastatic NSCLC with HER2 low or high expression: Cohort DTreatment being tested
Participants with metastatic NSCLC with HER2 low or high expression and/or HER2 mutation will receive SAR443216 as intravenous (IV) infusion.
Treatment: SAR443216 IV
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 1/1b Open-label, First-in-human, Single Agent, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors.
- Record updated
- 15 September 2025